# India Biologic Therapy Market > India Biologic Therapy Market Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) and By End User (Hospitals, Clinics, Home Healthcare) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.49% - **2024:** $ 15.43 Billion - **2025:** $ 15.97 Billion - **2035:** $ 22.5 Billion - **Key Players:** AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US), Merck & Co. (US) **Report ID:** MRFR/Pharma/52749-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-biologic-therapy-market-54512 --- ## Market Summary ## **India Biologic Therapy Market Overview** As per MRFR analysis, the India Biologic Therapy Market Size was estimated at 14.91 (USD Billion) in 2023.The India Biologic Therapy Market Industry is expected to grow from 15.7(USD Billion) in 2024 to 22.5 (USD Billion) by 2035. The India Biologic Therapy Market CAGR (growth rate) is expected to be around 3.326% during the forecast period (2025 - 2035). **Key India Biologic Therapy Market Trends Highlighted** The India Biologic Therapy Market is currently experiencing significant growth driven by several key factors. There is an increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which has led to a higher demand for biologic therapies that offer targeted treatment options. Additionally, advancements in biotechnology and increased investment in research and development are propelling the market forward. The Indian government is promoting initiatives that support the development of biologics, further enhancing the environment for innovation in this sector.  Opportunities in the India Biologic Therapy Market are abundant, particularly in biosimilars, which are gaining popularity due to their cost-effectiveness compared to original biologics.As the regulatory framework in India becomes more conducive to the approval of these therapies, companies can explore partnerships and collaborations to bring new products to market more efficiently. Furthermore, the growing awareness among healthcare professionals and patients about the benefits and availability of biologic treatments presents a significant potential for market expansion. In recent times, there has been a marked trend towards personalized medicine in the Indian healthcare landscape.  This shift is encouraging pharmaceutical companies to focus on developing tailored biologic therapies that cater to individual patient needs. Biologic therapies are also being integrated into treatment protocols for various diseases, leading to better patient outcomes and improved quality of life.As more stakeholders recognize the importance of biologics, including healthcare providers and insurers, the overall accessibility and acceptance of these therapies are expected to increase, further boosting the market in India. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Biologic Therapy Market Drivers** **Growing Burden of Autoimmune Disorders** In India, the prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis has been on the rise, contributing significantly to the India Biologic Therapy Market Industry. According to the Indian Council of Medical Research, autoimmune diseases affect around 10% of the Indian population, with studies indicating that this figure has steadily increased over the last decade.  The increasing awareness and diagnosis of these conditions have led to a growing demand for biologic therapies, which are specifically designed to target and manage such diseases.Established pharmaceutical firms like Biocon and Dr. Reddy's Laboratories are actively investing in Research and Development for biologic treatments, enhancing their portfolios to meet the rising healthcare needs associated with autoimmune disorders. This focus on R&D is expected to propel market growth as more effective therapies become available to address this growing health concern. **Rising Cancer Incidence Rate** The cancer incidence rate in India is escalating, creating a pressing demand for advanced treatment options, especially biologic therapies. Reports from the National Cancer Registry suggest that the annual incidence of cancer cases has reached approximately 1.3 million, with projections indicating a 25% increase in the next decade.  This growing patient population requires innovative treatment solutions, particularly biologics, which have shown promise in treating various cancers.Prominent players like Roche and Novartis are actively involved in the Indian market, contributing to the development and availability of biologic therapies tailored to the needs of cancer patients. Their presence and investment in clinical trials and innovative therapies play a crucial role in shaping the India Biologic Therapy Market Industry. **Government Initiatives Supporting Biologics Development** The Indian government has initiated several programs aimed at promoting the biopharmaceutical sector, which includes biologic therapies. By 2025, the Indian government's vision includes increasing the biopharmaceutical market's valuation significantly, with specific incentives for Research and Development as detailed in the Biotechnology Strategy 2022.  Additionally, the Department of Biotechnology is facilitating the establishment of bioclusters across the nation which will boost collaboration and innovation in biologics.Such proactive government support not only encourages domestic firms but also attracts foreign investment, thereby enhancing the India Biologic Therapy Market Industry's growth potential. This commitment from the government supports the establishment of a robust framework for the advancements in biologic therapies. **Increase in Healthcare Spending** India's healthcare spending has been steadily increasing, contributing to the growth of various healthcare segments, including the India Biologic Therapy Market Industry. According to the Ministry of Health and Family Welfare, the healthcare expenditure in India is projected to reach 3.5 trillion USD by 2025.  This increase in budget allocation allows for broader access to advanced treatment options such as biologic therapies, especially for chronic and complex conditions.Major pharmaceutical companies like Sanofi and AbbVie are expanding their operations in India, aiming to meet the rising demand for biologics as part of their strategy to capitalize on increased healthcare spending. Such expansions and product launches will positively impact the biologic therapy market, ensuring better access for patients across the country. **India Biologic Therapy Market Segment Insights** **Biologic Therapy Market Therapy Type Insights** The Therapy Type segment within the India Biologic Therapy Market reflects a diverse array of treatment options that are transforming healthcare across the nation. Biologic therapies are increasingly recognized for their efficacy in treating complex conditions such as autoimmune diseases, cancers, and genetic disorders. Monoclonal antibodies represent a significant portion of this market, known for their ability to target specific pathways, thereby minimizing side effects and maximizing therapeutic impact.  They have been pivotal in the treatment landscape for conditions like rheumatoid arthritis and certain types of cancer, attracting substantial interest from both healthcare providers and patients. Vaccines, another critical component, play an essential role in preventive healthcare. In India, the surge in vaccine development, particularly against infectious diseases, underscores their importance in public health strategies. As the government and private sector invest in Research and Development for innovative vaccine formulations, the Indian population benefits from increased immunity, thereby decreasing disease prevalence.  Cell therapy is also gaining traction, characterized by its regenerative potential. This therapy harnesses the body's own cellular mechanisms to repair damaged tissues or organs, representing a remarkable approach particularly in the management of degenerative diseases and advanced cancers. With the advancement of technologies facilitating cell culture and manipulation, India is positioned to become a prominent player in cell therapy.Gene therapy, while still in its developmental stages, offers promising opportunities by directly addressing genetic disorders at the cellular level. The potential to rectify genetic faults before symptoms manifest could revolutionize treatment methodologies across various hereditary conditions.  The Indian regulatory environment is beginning to adapt to accommodate these innovative therapies, thereby enhancing patient access.The overall dynamics within the India Biologic Therapy Market are influenced by a combination of rising healthcare awareness, government investments in life sciences, and the increasing prevalence of chronic diseases. As healthcare systems evolve, the Therapy Type segment will continue to expand, reflecting a growing inclination towards personalized medicine that aligns patient needs with therapeutic advancements in India. The interplay of these factors will drive sustained market growth and foster a more robust ecosystem for biologic therapies in the years to come. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Biologic Therapy Market Application Insights** The India Biologic Therapy Market has a strong structure in its Application sector, which includes crucial areas like Oncology, Autoimmune Diseases, Infectious Diseases, and Cardiovascular Diseases. Oncology stands out as a critical subject because of the increased cancer prevalence in India, which is driving need for tailored medicines that improve patient outcomes. Autoimmune diseases are another important topic, indicating the rising occurrence of disorders such as rheumatoid arthritis and lupus, demanding appropriate biological therapies. Infectious Diseases are a major focus as India's health policies strive to mitigate the impact of epidemics, fostering innovations in biologic therapies. Furthermore, the growing burden of Cardiovascular Diseases, attributed to urbanization and lifestyle changes, highlights the importance of biologic treatments tailored to improve heart health. As healthcare infrastructure improves, each of these segments presents ample opportunities for expansion and innovation, supported by favorable government initiatives aimed at elevating biopharmaceutical research and access across the region, ultimately contributing to a progressive trajectory in the India Biologic Therapy Market. **Biologic Therapy Market Route of Administration Insights** The Route of Administration segment plays a critical role in the India Biologic Therapy Market, influencing patient outcomes and treatment accessibility. Intravenous administration is widely recognized for its effectiveness in delivering biologics rapidly into the bloodstream, making it essential for acute treatments and hospital settings. Subcutaneous administration has gained prominence due to its convenience, allowing patients to self-administer therapies at home, thereby enhancing adherence and improving quality of life.  Intramuscular administration remains significant, particularly for vaccines and certain hormone therapies, due to its relatively simple technique and widespread acceptance in clinical environments.As the landscape of biologic therapies continues to evolve, advancements in formulation and delivery technologies are anticipated to further optimize these routes, fostering growth in the market. The increasing prevalence of chronic diseases and an aging population in India are expected to drive demand for these therapies, highlighting the importance of understanding the dynamics within this Route of Administration segment and its contribution to the overall India Biologic Therapy Market revenue. **Biologic Therapy Market End User Insights** The End User segment of the India Biologic Therapy Market plays a vital role in catering to the growing demand for advanced therapeutic solutions. Hospitals form a critical component of this market, equipped with the infrastructure and professional expertise to deliver biologic therapies to a diverse patient population. Clinics also contribute significantly by providing accessible outpatient care, focusing on personalized treatments and managing chronic conditions effectively.  Home Healthcare has gained prominence in recent years, reflecting a shift towards patient-centric care strategies that prioritize comfort and convenience, allowing patients to receive therapies in the comfort of their homes while reducing hospital congestion.The increasing prevalence of chronic diseases and the need for innovative treatment solutions drive the growth of these end-user sectors, presenting opportunities for advancements in biologic therapies. Additionally, the rising aging population in India further fuels the demand across these end-user categories, creating a landscape ripe for growth and innovation in the India Biologic Therapy Market. Understanding the dynamics and trends within the End User segment is crucial for stakeholders aiming to leverage the opportunities presented by this evolving market landscape. **India Biologic Therapy Market Key Players and Competitive Insights** The Indian Biologic Therapy Market has been showing dynamic growth, characterized by an increasing demand for therapeutic options that leverage biological processes to treat various chronic and complex diseases. The competitive landscape is shaped by various local and multinational companies that innovate and expand their portfolios through strategic partnerships, research and development, and targeted marketing efforts. With the government promoting initiatives to make biologic therapies more accessible and affordable, companies are vying for a foothold in this lucrative sector. The interplay of regulatory frameworks, technological advancements, and heightened patient awareness further contributes to a competitive environment where agility and innovation play crucial roles in determining market leaders. Gilead Sciences has established a significant presence in the Indian Biologic Therapy Market through its robust portfolio focused primarily on viral infections and oncology. The company has made considerable investments in research and development to cater to the needs of Indian patients, adapting its drug formulations and delivery methods to align better with local healthcare systems. Gilead's strengths in the market include its commitment to enhancing patient access to treatments, which often includes innovative pricing models and collaborations with local healthcare providers. The company has been actively involved in partnerships aimed at enhancing diagnostic capabilities and awareness about biologic therapies, positioning itself as a leader in the sector and earning the trust of healthcare professionals and patients alike. Novartis has also carved out a competitive position within the Indian Biologic Therapy Market, primarily focusing on therapies for conditions like cancers and immune disorders. The company's key products include monoclonal antibodies and gene therapies that have been tailored to meet the specific health needs of the Indian population. Novartis benefits from its strong research network in India, which allows it to develop localized solutions. The company has engaged in numerous strategic mergers and acquisitions to enhance its product pipeline and streamline its operations within the country. Its commitment to innovative healthcare solutions is underscored by its efforts to improve health literacy and patient engagement, fostering a loyal customer base. Through these strategic initiatives, Novartis continues to strengthen its market foothold while contributing positively to the evolving healthcare landscape in India. **Key Companies in the India Biologic Therapy Market Include:** - Gilead Sciences - Novartis - Merck - Sanofi - Eli Lilly - Amgen - Johnson & Johnson - Celgene - Zydus Cadila - AbbVie - BristolMyers Squibb - Dr. Reddy's Laboratories - Pfizer - Biocon - Roche **India Biologic Therapy Market Industry Developments** Recent developments in the India Biologic Therapy Market have been marked by significant activity from leading companies such as Gilead Sciences, Novartis, Merck, and others responding to the growing demand for innovative therapies. In August 2023, Eli Lilly announced an expansion plan to establish a new production facility in India, aimed at enhancing local manufacturing capabilities for biologic therapies, reflecting the nation's increasing importance in the global supply chain.  In September 2023, Zydus Cadila launched a biosimilar of a monoclonal antibody, increasing access to affordable treatment options for patients in India. Additionally, the market saw a noteworthy merger in July 2023, when AbbVie announced its acquisition of a biotech firm specializing in new biologic therapies, enhancing its portfolio in immune-oncology.  With the overall market growing rapidly, the Indian biologics sector is projected to reach approximately USD 15 billion by 2025, driven by increased prevalence of chronic diseases and favorable government policies. In the last few years, there has been a strong push for Research and Development initiatives, with companies like Biocon and Roche making significant investments to boost innovation in the biologic therapy landscape in India. **India Biologic Therapy Market Segmentation Insights** **Biologic Therapy Market Therapy Type Outlook** - Monoclonal Antibodies - Vaccines - Cell Therapy - Gene Therapy **Biologic Therapy Market Application Outlook** - Oncology - Autoimmune Diseases - Infectious Diseases - Cardiovascular Diseases **Biologic Therapy Market Route of Administration Outlook** - Intravenous - Subcutaneous - Intramuscular **Biologic Therapy Market End User Outlook** - Hospitals - Clinics - Home Healthcare ## Market Drivers ### Advancements in Biotechnology Technological advancements in biotechnology are propelling the growth of the biologic therapy market in India. Innovations in genetic engineering, monoclonal antibody production, and cell therapy are transforming the landscape of treatment options available. The biologic therapy market is benefiting from these advancements, as they enable the development of more effective and targeted therapies. For instance, the introduction of biosimilars has made biologic treatments more accessible and affordable, potentially increasing patient access to these therapies. The Indian biotechnology sector is projected to reach $100 B by 2025, indicating a robust growth trajectory that will likely enhance the biologic therapy market. Additionally, collaborations between research institutions and pharmaceutical companies are fostering an environment conducive to innovation, further driving the market forward. ### Rising Healthcare Expenditure The increase in healthcare expenditure in India is a crucial driver for the biologic therapy market. As the country experiences economic growth, healthcare spending is projected to rise, with estimates suggesting an increase to 3.5% of GDP by 2025. This growing investment in healthcare infrastructure and services is likely to enhance access to advanced treatment options, including biologics. The biologic therapy market stands to gain from this trend, as healthcare providers seek to incorporate innovative therapies into their treatment protocols. Additionally, the rising disposable income among the population is enabling more individuals to seek advanced medical care, further propelling the demand for biologic therapies. This trend indicates a shift towards prioritizing quality healthcare, which is essential for the growth of the biologic therapy market. ### Government Initiatives and Policies Government initiatives aimed at promoting healthcare access and affordability are significantly impacting the biologic therapy market. The Indian government has implemented various policies to encourage the development and distribution of biologics, including tax incentives and streamlined regulatory processes. These initiatives are designed to enhance the availability of advanced therapies, particularly in underserved regions. The biologic therapy market is likely to benefit from these supportive measures, as they facilitate faster market entry for new products. Furthermore, the National Health Policy emphasizes the importance of affordable healthcare, which aligns with the growing demand for cost-effective biologic treatments. As a result, the market is expected to expand, driven by both public and private sector investments in biologic therapies. ### Growing Awareness and Patient Advocacy There is a notable increase in awareness regarding chronic diseases and the benefits of biologic therapies among the Indian population. Patient advocacy groups are playing a pivotal role in educating individuals about treatment options, thereby driving demand for biologics. The biologic therapy market is experiencing a shift as patients become more informed and proactive about their health choices. This growing awareness is leading to higher patient engagement in treatment decisions, which is likely to influence prescribing patterns among healthcare professionals. Furthermore, social media and digital platforms are facilitating the dissemination of information, making it easier for patients to access knowledge about biologic therapies. As a result, the market is expected to expand, driven by a more informed patient base advocating for advanced treatment options. ### Increasing Prevalence of Chronic Diseases The rising incidence of chronic diseases in India, such as diabetes, cancer, and autoimmune disorders, is a primary driver for the biologic therapy market. As per recent health reports, chronic diseases account for approximately 60% of all deaths in the country. This alarming statistic underscores the urgent need for effective treatment options, particularly biologics, which offer targeted therapies that can significantly improve patient outcomes. The biologic therapy market is witnessing a surge in demand as healthcare providers seek innovative solutions to manage these conditions. Furthermore, the increasing burden of chronic diseases is prompting both public and private sectors to invest in advanced therapeutic options, thereby expanding the market landscape. The focus on personalized medicine is also gaining traction, as biologics can be tailored to individual patient profiles, enhancing their efficacy and safety. ## Future Outlook The [Biologic Therapy Market](https://www.marketresearchfuture.com/reports/biologic-therapy-market-840) is projected to grow at a 3.49% CAGR from 2025 to 2035, driven by increasing chronic disease prevalence, technological advancements, and enhanced healthcare access. **New opportunities:** - Development of personalized biologic therapies targeting specific patient demographics. - Expansion of telehealth services for biologic therapy consultations and follow-ups. - Investment in advanced manufacturing technologies for cost-effective biologic production. By 2035, the biologic therapy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Monoclonal Antibodies (Largest) vs. Cell Therapy (Fastest-Growing) The India biologic therapy market demonstrates a diverse landscape defined by several key segments. Among these, monoclonal antibodies hold the largest market share, driven by their established role in treating various chronic diseases. Vaccines also contribute significantly, fueled by ongoing public health initiatives. Meanwhile, cell therapy, with its innovative approaches, is garnering interest, leading to rapid growth within the sector. Growth trends within this segment are notably influenced by advancements in biotechnology and increasing investments in research and development. As healthcare providers seek more effective treatments, gene therapy is emerging as a promising alternative, showing substantial potential for future expansion. Moreover, the overall rise in healthcare awareness and a robust regulatory framework are propelling these segments forward, enhancing their market positions. Monoclonal Antibodies (Dominant) vs. Cell Therapy (Emerging) Monoclonal antibodies are recognized as the dominant force in the India biologic therapy market, largely owing to their targeted action and proven efficacy in chronic disease management. They offer high specificity, resulting in fewer side effects compared to traditional therapies. On the other hand, cell therapy is positioned as an emerging player, characterized by its innovative techniques that harness the body’s own cells to combat diseases. This segment benefits from increasing research investments and a strong scientific base, which are crucial for its growth. While monoclonal antibodies continue to lead, cell therapy's rapid advancements in personalized medicine and regenerative treatment are drawing significant attention, making it a future focal point in the market. ### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) Within the application segment, Oncology holds the largest share, driven by a surge in cancer cases and advancements in targeted therapies. Autoimmune Diseases, while currently smaller, showcase the fastest growth thanks to increasing awareness and innovations in treatment options that cater specifically to this segment. The distribution reflects the ongoing commitment to addressing chronic and complex conditions through biologic therapies. The growth trends in the application segment are propelled by both technological advancements and changing patient demographics. The rise in elderly populations is contributing to an increase in age-related diseases, while the enhanced capabilities of biologic therapies are making them more appealing than traditional treatments. Moreover, the growing investment in research and development is expected to further fuel this growth, particularly in the areas of Oncology and Autoimmune Diseases. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) Oncology is positioned as the dominant application segment in the biologic therapy market, characterized by a wide array of innovative therapies tailored to combat various cancer types. The high incidence of cancer has led to significant investment in research and development, pushing the boundaries of treatment options. In contrast, Autoimmune Diseases are emerging as a rapidly growing segment, reflecting a shift in focus to conditions like rheumatoid arthritis and lupus. Recent advancements in biologic therapies aimed at modulating immune responses have garnered substantial attention, highlighting the importance of personalized medicine approaches in effectively managing these complex disorders. This dual focus on both Oncology and Autoimmune Diseases illustrates the dynamic and evolving landscape of therapeutic applications. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) Intravenous therapy leads the market in terms of share within the India biologic therapy market, primarily due to its effectiveness in delivering biologics directly into the bloodstream for rapid onset of action. Subcutaneous administration is gaining traction as it offers patients more convenience and flexibility, resulting in a stronger market position among alternative administration routes. The intramuscular segment, while present, reflects slower adoption rates compared to its counterparts. Growth in this segment is being driven largely by advancements in biologic formulations that cater to ease of administration. As patient-centric solutions gain importance, subcutaneous routes are being preferred for conditions like rheumatoid arthritis and psoriasis. Increasing research and development aimed at enhancing delivery mechanisms also support the rapid growth of the subcutaneous segment, alongside a growing focus on personalized medicine. Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous administration is the dominant route in the biologic therapy market, widely recognized for its reliability in ensuring complete bioavailability of therapeutic agents. It is especially preferred for acute conditions requiring immediate therapeutic effects. In contrast, subcutaneous administration is emerging as a popular alternative due to its ability to be self-administered by patients, thus promoting adherence and improving quality of life. This ease of use aligns perfectly with today's focus on patient-centered care, driving demand in chronic disease management. Both routes play crucial roles, with intravenous remaining the standard for many hospital therapies, while subcutaneous continues to gain ground in outpatient settings. ### By End-user: Hospitals (Largest) vs. Home Healthcare (Fastest-Growing) In the India biologic therapy market, hospitals hold the largest share among the end-user segments, reflecting their pivotal role in patient care and advanced treatment options. Clinics follow as a significant contributor, while home healthcare emerges as a notable contender, gradually increasing its market presence and catering to the growing preference for personalized at-home treatments. The growth trends within this segment reveal a shift towards greater reliance on home healthcare solutions, driven by advancements in telemedicine and a rising aging population seeking convenient treatment options. Meanwhile, hospitals continue to play a dominant role due to their comprehensive services, but the increasing demand for outpatient care and reduced hospital stays present opportunities for clinics and home healthcare services to expand their reach significantly. Hospitals: Dominant vs. Home Healthcare: Emerging Hospitals are characterized by their extensive infrastructure and capabilities to administer complex biologic therapies, making them the dominant force in the market. They offer a wide range of services, equipped with advanced technologies and skilled professionals that cater to diverse patient needs. Conversely, home healthcare is emerging as a vital segment, driven by consumer demand for more personalized and accessible care. With innovations in medical technology, patients can now receive effective biologic therapies at home, leading to increased comfort and improved adherence to treatment protocols. This segment's growth is further fueled by the increasing focus on cost-effective healthcare solutions, allowing for a more flexible approach to patient management. ## Competitive Benchmarking The biologic therapy market in India is characterized by a dynamic competitive landscape, driven by increasing healthcare demands and advancements in biotechnology. Major players such as AbbVie (US), Roche (CH), and Johnson & Johnson (US) are strategically positioned to leverage innovation and expand their market presence. AbbVie (US) focuses on enhancing its portfolio through research and development, particularly in immunology and oncology, while Roche (CH) emphasizes personalized medicine and diagnostics. Johnson & Johnson (US) adopts a multifaceted approach, integrating digital health solutions into its biologic offerings, thereby enhancing patient engagement and treatment outcomes. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient-centric solutions.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and therapies, catering to various patient needs while fostering competition among established and emerging companies. In October AbbVie (US) announced a strategic partnership with a leading Indian biotech firm to co-develop a novel biologic therapy targeting autoimmune diseases. This collaboration is expected to accelerate the development process and enhance AbbVie's market penetration in India, aligning with its focus on innovative treatment solutions. The partnership underscores the importance of local expertise in navigating regulatory landscapes and addressing specific patient needs. In September Roche (CH) launched a new biologic therapy for breast cancer in India, which incorporates advanced biomarker testing to tailor treatment plans. This launch not only reinforces Roche's commitment to personalized medicine but also positions the company as a leader in innovative cancer therapies. The integration of biomarker testing is likely to improve patient outcomes and solidify Roche's competitive edge in the oncology segment. In August Johnson & Johnson (US) expanded its biologic therapy portfolio by acquiring a promising startup specializing in gene therapy. This acquisition is anticipated to enhance Johnson & Johnson's capabilities in developing cutting-edge treatments, particularly in rare diseases. The move reflects a broader trend of consolidation within the industry, as established players seek to bolster their innovation pipelines through strategic acquisitions. As of November current competitive trends in the biologic therapy market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, as companies that prioritize these elements could gain a substantial advantage in the rapidly evolving biologic therapy sector. ## Recent News & Developments Recent developments in the India Biologic Therapy Market have been marked by significant activity from leading companies such as Gilead Sciences, Novartis, Merck, and others responding to the growing demand for innovative therapies. In August 2023, Eli Lilly announced an expansion plan to establish a new production facility in India, aimed at enhancing local manufacturing capabilities for biologic therapies, reflecting the nation's increasing importance in the global supply chain.  In September 2023, Zydus Cadila launched a biosimilar of a monoclonal antibody, increasing access to affordable treatment options for patients in India. Additionally, the market saw a noteworthy merger in July 2023, when AbbVie announced its acquisition of a biotech firm specializing in new biologic therapies, enhancing its portfolio in immune-oncology.  With the overall market growing rapidly, the Indian biologics sector is projected to reach approximately USD 15 billion by 2025, driven by increased prevalence of chronic diseases and favorable government policies. In the last few years, there has been a strong push for Research and Development initiatives, with companies like Biocon and Roche making significant investments to boost innovation in the biologic therapy landscape in India. ## Report Scope | MARKET SIZE 2024 | 15.43(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 15.97(USD Billion) | | MARKET SIZE 2035 | 22.5(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.49% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Amgen (US), Roche (CH), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), Sanofi (FR), Gilead Sciences (US), Merck & Co. (US) | | Segments Covered | Type, Application, Route of Administration, End-user | | Key Market Opportunities | Emerging gene therapies and personalized medicine are reshaping the biologic therapy market landscape. | | Key Market Dynamics | Rising demand for personalized biologic therapies drives innovation and competition in the Indian market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the India biologic therapy market in 2024?** A: The market valuation of the India biologic therapy market was $15.43 Billion in 2024. **Q: What is the projected market valuation for the India biologic therapy market by 2035?** A: The projected market valuation for the India biologic therapy market is $22.5 Billion by 2035. **Q: What is the expected CAGR for the India biologic therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the India biologic therapy market during the forecast period 2025 - 2035 is 3.49%. **Q: Which segment is projected to have the highest valuation in the India biologic therapy market by 2035?** A: The Cell Therapy segment is projected to reach $6.0 Billion by 2035. **Q: What are the key applications driving the India biologic therapy market?** A: Key applications include Oncology, Autoimmune Diseases, Infectious Diseases, and Cardiovascular Diseases. **Q: Which route of administration is expected to dominate the India biologic therapy market?** A: The Subcutaneous route of administration is expected to dominate, projected to reach $9.0 Billion by 2035. **Q: What is the expected market size for Home Healthcare in the India biologic therapy market by 2035?** A: The Home Healthcare segment is expected to reach $10.5 Billion by 2035. **Q: Who are the leading players in the India biologic therapy market?** A: Leading players include AbbVie, Amgen, Roche, Johnson & Johnson, and Novartis. **Q: What was the valuation of the Oncology application in the India biologic therapy market in 2024?** A: The valuation of the Oncology application was $3.5 Billion in 2024. **Q: How does the market for Monoclonal Antibodies compare to that of Gene Therapy in 2035?** A: By 2035, the market for Monoclonal Antibodies is projected to reach $7.0 Billion, compared to $5.0 Billion for Gene Therapy. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-biologic-therapy-market-54512*